Search

Ron Bentsur

from Tenafly, NJ
Age ~59
Get Report
Related to:
Raffaella A Garofanelli, 37Dan Bentsur, 54Isabella N Garofanelli, 39Dan Bentsur, 43Yaniv Klein, 47Israella KleinbentsurShira I Bentsur, 57Shira I Klein, 57
Connected to:
David N Bentti, 40Justin T Benttinen, 41Joseph M Bentvelzen, 88Jennifer L Bentwood, 50Joel L Bentwood, 68Jeffrey D Benty, 55Abbi R Bentz, 54Al Bentz, 80Alex C Bentz, 36Alexandra L Bentz, 31

Ron Bentsur Phones & Addresses

  • 212 Highwood Ave, Tenafly, NJ 07670 (201) 568-5448
  • 86 Hickory Ave, Tenafly, NJ 07670 (201) 568-0350 (201) 568-5448 (201) 894-0748
  • 341 E 76Th St #3FE, New York, NY 10021 (212) 744-3238
  • Berlin, NJ

Work

Company: Xtl biopharmaceuticals ltd. Position: Ceo

Education

Degree: Associate degree or higher

Industries

Biotechnology

Resumes

Resumes

Ron Bentsur Photo 1

Chief Executive Officer

View page
Location:
Valley Cottage, NY
Industry:
Biotechnology
Work:
XTL Biopharmaceuticals Ltd.
CEO

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ron Bentsur
Director
Stemline Therapeutics Inc.
Biotechnology · Commercial Physical Research · Pharmaceutical Preparations
1675 York Ave, New York, NY 10128
Ivan Bergstein Md 750 Lexington Ave / 11, New York, NY 10022
750 Lexington Ave 11, New York, NY 10022
750 Lexington Ave, New York, NY 10022
(646) 502-2311, (646) 389-0968, (212) 831-1111
Ron Bentsur
MEDCLIPS.COM NETWORK, INC
750 Lexington Ave 20 Flr, New York, NY 10022
Ron Bentsur
NERYX BIOPHARMACEUTICALS, INC
Pharmaceutical Products Wholesale & Manufacturers
750 Lexington Ave 20, New York, NY 10022
(212) 531-5965, (212) 531-5961
Ron Bentsur
CEO
XTL BIOPHARMACEUTICALS LTD
Research & Development in Biotechnology
C/O Alston & Bird Llp 90 Park Ave, New York, NY 10016
711 Executive Blvd STE Q, Valley Cottage, NY 10989
(845) 267-0707, (845) 267-0926
Ron Bentsur
CEO, Chairman
KERYX BIOPHARMACEUTICALS INC
Pharmaceutical Preparations & Medical Research · Pharmaceutical Preparation Mfg
750 Lexington Ave FL 20, New York, NY 10022
750 Lexington Ave - 20, New York, NY 10022
(212) 531-5965, (212) 531-5961, (646) 825-9300
Ron Bentsur
ACCUMIN DIAGNOSTICS, INC
Medical Laboratory
750 Lexington Ave, New York, NY 10022
750 Lexington Ave 20, New York, NY 10022
C/O Keryx 750 Lexington Ave 20, New York, NY 10022
Ron Bentsur
AOI PHARMACEUTICALS, INC
Pharmaceutical Products Wholesale & Manufacturers
750 Lexington Ave, New York, NY 10022
750 Lexington Ave 20, New York, NY 10022
(212) 531-5965, (212) 531-5961
Ron Bentsur
Principal
Amnalon LLC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
212 Highwood Ave, Tenafly, NJ 07670

Publications

Us Patents

Use Of Ferric Citrate In The Treatment Of Chronic Kidney Disease Patients

View page
US Patent:
20130345303, Dec 26, 2013
Filed:
Jun 21, 2013
Appl. No.:
13/924332
Inventors:
Ron Bentsur - Tenafly NJ, US
International Classification:
A61K 31/295
US Classification:
514502
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.

Use Of Ferric Citrate In The Treatment Of And The Reduction Of Mortality And Morbidity Related To Adverse Cardiac Events In Chronic Kidney Disease Patients

View page
US Patent:
20190307791, Oct 10, 2019
Filed:
Dec 11, 2018
Appl. No.:
16/216772
Inventors:
- New York NY, US
Ron BENTSUR - Tenafly NJ, US
James F. OLIVIERO - New York NY, US
Assignee:
KERYX BIOPHARMACEUTICALS, INC. - New York NY
International Classification:
A61K 33/26
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.

Use Of Ferric Citrate In The Treatment Of Chronic Kidney Disease Patients

View page
US Patent:
20190269645, Sep 5, 2019
Filed:
Oct 8, 2018
Appl. No.:
16/154268
Inventors:
- Boston MA, US
Ron Bentsur - Tenafly NJ, US
Assignee:
Keryx Biopharmaceuticals, Inc. - Boston MA
International Classification:
A61K 31/295
A61K 9/28
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.

Use Of Ferric Citrate In The Treatment Of Iron-Deficiency Anemia

View page
US Patent:
20180071243, Mar 15, 2018
Filed:
Mar 3, 2016
Appl. No.:
15/553348
Inventors:
- Ney York NY, US
Ron Bentsur - Tenafly NJ, US
Shay David Shemesh - Camas WA, US
Assignee:
Keryx Biopharmaceuticals, Inc. - Boston MA
International Classification:
A61K 31/295
A61K 9/00
A61K 9/20
Abstract:
Described herein are methods for treating patients with iron-deficiency anemia (IDA), comprising administering ferric citrate to such patients. In certain aspects, the patients treated for iron-deficiency anemia have a gastrointestinal disorder, such as inflammatory bowel disease, inflammatory bowel syndrome, Crohn's disease, microscopic colitis (such as collagenous or lymphocytic colitis), or chemically-induced colitis (e.g., NSAID (nonsteroidal anti-inflammatory drug)-induced colitis). In certain aspects, the patients treated for iron-deficiency anemia have blood loss associated with childbirth, menstruation or infection. In some aspects, the patients treated for iron-deficiency anemia have insufficient dietary intake of iron and/or insufficient absorption of iron.

Use Of Ferric Citrate In The Treatment Of And The Reduction Of Mortality And Morbidity Related To Adverse Cardiac Events In Chronic Kidney Disease Patients

View page
US Patent:
20160256486, Sep 8, 2016
Filed:
Nov 3, 2014
Appl. No.:
15/031678
Inventors:
- New York NY, US
Ron Bentsur - Tenafly NJ, US
Assignee:
Keryx Biopharmaceuticals, Inc. - New York NY
International Classification:
A61K 33/26
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.

Use Of Ferric Citrate In The Treatment Of Chronic Kidney Disease Patients

View page
US Patent:
20150079168, Mar 19, 2015
Filed:
Oct 24, 2014
Appl. No.:
14/523656
Inventors:
- New York NY, US
Ron Bentsur - Tenafly NJ, US
Assignee:
KERYX BIOPHARMACEUTICALS, INC. - New York NY
International Classification:
A61K 31/295
A61K 9/28
US Classification:
424465, 514502
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.

Use Of Ferric Citrate In The Treatment Of Chronic Kidney Disease Patients

View page
US Patent:
20140234416, Aug 21, 2014
Filed:
Apr 25, 2014
Appl. No.:
14/262465
Inventors:
- New York NY, US
Ron Bentsur - Tenafly NJ, US
Assignee:
Keryx Biopharmaceuticals, Inc. - New York NY
International Classification:
A61K 31/295
A61K 9/28
US Classification:
424465, 514502
Abstract:
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
Control profile
Ron Bentsur from Tenafly, NJ, age ~59 Get Report